House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Oncology

Prostate cancer

EAU · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

Selected EAU 2026 prostate cancer recommendations covering informed PSA testing, MRI-directed diagnosis, risk-adapted staging, active surveillance, local treatment and metastatic therapy. Decisions depend on stage, grade, life expectancy, fitness, previous therapy and molecular findings, with ongoing attention to bone and metabolic health.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Risk-informed early detection

  • Discuss individualised early detection with well-informed men whose life expectancy is at least 15 years. Stop early diagnosis when life expectancy or performance status makes benefit unlikely; men expected to live less than 15 years are unlikely to benefit. [1]
  • Offer PSA testing from age 50, from 45 for African ancestry or a family history of prostate cancer before age 60, and from 40 for BRCA2 carriers, after an informed discussion. These thresholds belong to the EAU risk-adapted framework. [1]
  • In asymptomatic men with an initial PSA of 3–10 ng/mL, repeat PSA before further investigation. For PSA of 3–20 ng/mL, use prostate MRI or consider a correctly population-calibrated risk calculator or additional serum/urine biomarker to determine biopsy need. [1]
  • Provide genetic counselling before germline testing. Offer testing when the family history includes high-risk germline mutations or multiple cancers on one side, and when somatic testing identifies BRCA mutations. [1]

MRI, biopsy and staging

  • Perform MRI before biopsy when organ-confined prostate cancer is suspected, using PI-RADS acquisition and interpretation standards. MRI is not recommended as the initial population screening test. For a positive MRI with PI-RADS at least 4, targeted plus perilesional sampling is a weak recommendation. [1]
  • Prefer transperineal biopsy for lower infection risk and better antibiotic stewardship, with routine perineal skin disinfection. Omitting perioperative antibiotics in patients without infection risk factors is a weak recommendation. Submit cores from different sites separately for pathology. [1]
  • Do not add staging imaging for low-risk or favourable intermediate-risk localised disease. For unfavourable intermediate-risk disease, consider PSMA PET/CT if available or abdominal/pelvic cross-sectional imaging plus bone scan; this screening is strongly recommended for high-risk or locally advanced disease. [1]

Life expectancy and active surveillance

  • Base management on individual life expectancy, health and comorbidity. Use G8, mini-COG and Clinical Frailty Scale screening, with specialist geriatric assessment for G8 at most 14. Adapt treatment or use watchful waiting for irreversible impairment; provide symptom-directed palliation for frail patients. [1]
  • Active surveillance is standard for suitable low-risk disease and selected favourable intermediate-risk disease. Exclude cribriform or intraductal histology and ISUP grade group 3. In low-risk disease with life expectancy below ten years, use watchful waiting rather than a curative surveillance strategy. [1]
  • Active surveillance requires a strict protocol: PSA at least every six months, rectal examination and repeat biopsy with or without MRI every 2–3 years until life expectancy falls below ten years. Rising PSA with doubling time under three years prompts MRI and repeat biopsy; treatment change should depend on biopsy progression rather than PSA, MRI or examination alone. [1]

Local and locally advanced treatment

  • For intermediate-risk disease, offer radical prostatectomy when life expectancy exceeds ten years. Nerve-sparing surgery is appropriate on a side with low extracapsular-disease risk; low-dose-rate brachytherapy is an option for favourable intermediate risk with good urinary function. [1]
  • Intermediate-risk external-beam IMRT/VMAT with image guidance is combined with short-term ADT for four to six months. For high-risk localised disease, combine this radiation approach with long-term ADT for two to three years; radiation fractionation and organ-at-risk constraints require specialist planning. [1]
  • For locally advanced cN0M0 disease with at least two of cT3–4, Gleason score at least 8 or PSA at least 40 ng/mL, offer prostate radiation with long-term ADT and two years of abiraterone. For cN1M0, the recommended radiation field includes prostate and pelvis with long-term ADT and two years of abiraterone. [1]
  • Restrict whole-gland or focal ablation for intermediate-risk disease to trials or registries. Do not offer focal or whole-gland ablative treatment for high-risk localised or locally advanced disease. [1]

Hormone-sensitive metastatic disease

  • Discuss hormone-sensitive metastatic disease in a multidisciplinary team. Give immediate ADT for symptomatic M1 disease. With impending spinal cord compression or bladder outlet obstruction, start an LHRH antagonist or orchiectomy rather than risking agonist flare. [1]
  • Do not use ADT alone for first-presentation hormone-sensitive M1 disease when combination therapy is feasible, life expectancy is at least one year and the patient accepts additional harms. Offer ADT with abiraterone plus prednisone, apalutamide, enzalutamide or rezvilutamide in fit patients; ADT with darolutamide has a weak recommendation. [1]
  • When using docetaxel for hormone-sensitive M1 disease, offer it with ADT plus abiraterone or darolutamide in patients fit for docetaxel. Consider somatic or germline homologous-recombination-repair testing because selected patients may qualify for niraparib added to ADT and abiraterone. [1]
  • Offer prostate radiotherapy with ADT for first-presentation hormone-sensitive M1 disease with low volume by CHAARTED criteria. Do not combine ADT with surgery outside trials; metastasis-directed treatment belongs in trials or well-designed prospective cohorts. [1]

Castration resistance and molecular treatment

  • Confirm testosterone below 50 ng/dL before diagnosing castration resistance. Manage metastatic castration-resistant prostate cancer in a multidisciplinary team and obtain somatic/germline testing plus mismatch-repair or microsatellite-instability assessment if not already performed. [1]
  • For previously untreated metastatic castration-resistant disease without prior androgen-receptor pathway inhibitor treatment, genotype guides combinations: abiraterone–olaparib for HRR or BRCA mutation, abiraterone–niraparib for BRCA mutation, or enzalutamide–talazoparib for HRR mutation, provided the patient is fit for both agents. [1]
  • For metastatic castration-resistant disease, avoid routine sequencing of androgen-receptor-targeted drugs. Offer chemotherapy after prior androgen-receptor pathway inhibitor treatment, and PARP-inhibitor monotherapy to pretreated metastatic castration-resistant disease with relevant DNA repair mutations. Subsequent choice depends on prior treatment, fitness, symptoms, disease extent, genomics and preference. [1]
  • For nonmetastatic castration-resistant disease with PSA doubling time under ten months, offer apalutamide, darolutamide or enzalutamide to delay metastasis and improve survival. [1]

Follow-up and complications

  • During ADT, monitor PSA, testosterone and metabolic complications. Follow M1 patients at least every three to six months with regular imaging. Assess bone density at long-term ADT initiation, offer fracture protection during combination treatment, and provide calcium/vitamin D with denosumab or bisphosphonates while monitoring calcium. [1]
  • Treat painful bone metastases promptly with radiotherapy and appropriate analgesia. Spinal cord compression requires immediate high-dose corticosteroids and assessment for surgery, possibly followed by radiation; use radiation alone when surgery is unsuitable. [1]

Limitations and use

  • This selected summary does not reproduce all biopsy-avoidance thresholds, radiation schedules, postoperative salvage pathways, radioligand eligibility, drug doses or adverse-event protocols.
  • Several treatment recommendations use conventional bone-scan and CT/MRI staging; stage changes detected only by PSMA imaging require specialist interpretation rather than automatic extrapolation.
  • European treatment inclusion does not establish Indian approval or access. Molecular combinations need exact biomarker eligibility, previous-treatment review and current prescribing information.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Prostate cancer

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
EAU
Resource type
Clinical guideline · House clinical summary
Source setting
Europe

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Risk-informed early detection
  • MRI, biopsy and staging
  • Life expectancy and active surveillance
  • Local and locally advanced treatment
  • Hormone-sensitive metastatic disease
  • Castration resistance and molecular treatment
  • Follow-up and complications
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House